The Movement Disorders Prescriber's Guide to Parkinson's Disease

Erscheinungsjahr 2025
ISBN: 978-1-009-22261-7
Verlag: Cambridge University Press

Buch, Englisch, 350 Seiten, Format (B × H): 120 mm x 190 mm, Gewicht: 561 g

This concise, yet authoritative, clinical reference guide fulfils the needs of diverse clinicians, pharmacists and allied health professionals prescribing for Parkinson's disease and movement disorders in contemporary clinical practice. With chapters on newly approved drugs and their effects on motor and non-motor symptoms, information is also given on their use in particular populations including the elderly and patients with cognitive impairment. Each chapter includes pharmacological/biochemical rationale for drug use, a general guide to therapeutic use, pharmacokinetics, interaction profile, adverse effects, dosing and use, special population considerations, costs and value for money considerations, clinical vignette, a summary overview, and suggested reading. Ordered alphabetically and perfect for quick reference use, the guide is practical and essential for all prescribers with responsibility for patients with Parkinson's disease, including neurologists, geriatricians, internists, neurosurgeons, psychiatrists, family physicians, pharmacists as well as allied health professionals and resident, fellow, and student trainees in all related medical fields.

Autoren/Hrsg.

Chaudhuri, K. Ray

Jenner, Peter

Leta, Valentina

Jones, Shelley

Boura, Iro

Inhaltsverzeichnis

Foreword from Professor Chaudhuri; Introduction; Amantadine; Amitriptyline; Apomorphine Infusion; Apomorphine Injection; Apomorphine Sublingual; Botulinum; Citalopram; Clonazepam; Clozapine; Desimpramine; Domperidone; Donepezil; Droxidopa; Entacapone; Fludrocortisone; Glycopyrrolate; Istradefylline; Levodopa benserazide; Levodopa carbidopa; Levodopa carbidopa entacapone intestinal gel; Levodopa carbidopa intestinal gel; Levodopa inhaled; Lubipristone; Macrogol; Melatonin; Memantine; Midodrine; Mirabegron; Mirtazepine; Modafanil; Naltrexone; Nortriptyline; Opicapone; Oxybutynin; Piribedil; Pramipexole; Pimavenserin; Quetiapine; Rasagiline; Rivastigmine; Ropinirole; Rotigotine; Safinamide; Selegiline; Sildenafil; Solifenacin; Tolcapone; Tolterodine; Trihexyphenidyl; Venlafaxine; Zonisamide; Abbreviations.

Über Autor(innen)

Jenner, Peter
Professor Peter Jenner is an expert on the pharmacology of drugs and treatment strategies used at all stages of Parkinson's disease. He has been involved in the development and marketing of most of the key therapies. Peter has published over 700 papers on the cause, treatment and cure of Parkinson's disease.

Chaudhuri, K. Ray
Professor K. Ray Chaudhuri is Professor of Neurology/Movement Disorders at King's College Hospital and King's College London and the Director of the Parkinson Foundation International Centre of Excellence at King's College. He is ranked number 1 from the UK in terms of clinical expertise and publications by Expertscape, has over 550 publications and was cited as the most published in nonmotor aspects of Parkinson in a recent bibliometric review in 2024.

Boura, Iro
Dr Iro Boura is a neurologist currently working as a Ph.D. research fellow at the Neurology Laboratory, University of Crete and as a movement disorders consultant in the University Hospital of Heraklion, Crete (Greece). She is also affiliated with the Parkinson's Foundation of Centre of Excellence, Kings College Hospital and King's College London (UK).

Leta, Valentina
Dr Valentina Leta is a neurologist movement disorder specialist interested in infusion therapies and autonomic dysfunction in Parkinson's disease (PD). She has worked as principal/sub-investigator of numerous trials investigating the efficacy and safety of new drugs for PD. Dr Leta has been invited as a faculty at international conferences. She is author of over 55 peer-reviewed papers and book chapters on PD.

Jones, Shelley
Ms Shelley Jones is a consultant pharmacist in neurosciences, with over 16 years' experience working with people with Parkinson's and helping them to manage their medications optimally. Shelley has worked in the Parkinson's Centre of Excellence and been involved in publication of book chapters, papers and conference posters.